Our Focus on Immuno-Oncology

In the field of immuno-oncology, the STAM™ mouse is the most pathologically suitable model for developing new therapeutic drugs for liver cancer.

The utilization of STAM™ mouse enables non-clinical research for the development of liver cancer therapeutics targeting immune cells, tumor microenvironment, and genetic mutations.

READ MORE

NEWS RELEASE

A New Phase in MASH Therapeutics: Resmetirom (THR-β Agonist) and Semaglutide (GLP-1 Receptor Agonist)

In 2024, the U.S. FDA approved Resmetirom (a THR-β agonist) as the first therapeutic agent for MASH. In August…

READ MORE

Stem Cell Res Ther.

MicroRNA-4516 in extracellular vesicles-derived mesenchymal stem cells suppressed integrin αV-mediated lung fibrosis ( doi: 10.1186/s13287-025-04559-0.)

READ MORE

Made-to-Order Model

The Made-to-Order Model is a service offered by SMC Laboratories to support clients that are in need of a certain disease model that is not yet available on the market or not part of our current model catalog.

READ MORE

SERVICE

Search by topics

APAP-induced acute liver failure model

ALFmouse

LEARN MORE

STAM™ Model | MASH & Fibrosis & HCC

MASH/NASH-HCCmouse

LEARN MORE

Bleomycin-induced pulmonary fibrosis model

IPFmouse

LEARN MORE

Porcine Pancreatic Elastase (PPE) model

COPDmouse

LEARN MORE

CCl4-induced liver fibrosis model

Cirrhosismouse

LEARN MORE

New stage

Our service and disease mouse models bridge the development of the next- Generation Cancer Therapies in the field of Immuno-oncology.

LEARN MORE

New stage

SMC Laboratories,Inc.

COMPANY

At SMC Laboratories, we support drug research with our cutting-edge non-clinical pharmacology studies to quickly deliver therapeutic drugs to patients suffering from diseases that cannot be treated with existing drugs.

LEARN MORE

PUBLICATION

We, SMC Laboratories, are highly regarded worldwide as a consulting – based CRO that designs tailored to the needs of pharmaceutical companies and research institutions.

NEWS

2025.09.26

PRODUCTS AND SERVICE

Pulmonary Function Assessment in the Elastase-Induced Emphysema Model

At our company, we conduct preclinical evaluations using the elastase-induced emphysema (PPE: porcine pancreat…

READ MORE

2025.09.12

A New Positive Control Option in the UUO Model: Dapagliflozin

We have confirmed the renoprotective effect of the SGLT2 inhibitor dapagliflozin (20 mg/kg, oral administratio…

READ MORE

2025.08.28

PUBLICATION

Publication Announcement: Study Using Our IPF Model

A research article utilizing our bleomycin-induced pulmonary fibrosis (IPF) mouse model has been published in …

READ MORE

2025.08.15

NEWS RELEASE

A New Phase in MASH Therapeutics: Resmetirom (THR-β Agonist) and Semaglutide (GLP-1 Receptor Agonist)

In 2024, the U.S. FDA approved Resmetirom (a THR-β agonist) as the first therapeutic agent for MASH. In August…

READ MORE

2025.08.05

PRODUCTS AND SERVICE UPDATE

Clear Negative Correlation Between FVC and Ashcroft Score in Bleomycin-Induced Lung Fibrosis Model

In preclinical drug development for fibrotic lung diseases, the ability to quantitatively and reproducibly ass…

READ MORE

2025.07.25

PRODUCTS AND SERVICE

New Model Launch: Introduction of the Rat CCl₄-Induced Acute Liver Injury Model

SMC Laboratories is pleased to announce the launch of a new in vivo platform: the rat CCl₄ (carbon tetrachlori…

READ MORE